13.89
Schlusskurs vom Vortag:
$13.55
Offen:
$13.51
24-Stunden-Volumen:
836.89K
Relative Volume:
0.72
Marktkapitalisierung:
$986.12M
Einnahmen:
$114.04M
Nettoeinkommen (Verlust:
$-330.15M
KGV:
-2.9366
EPS:
-4.73
Netto-Cashflow:
$-274.85M
1W Leistung:
+0.58%
1M Leistung:
+13.76%
6M Leistung:
+403.26%
1J Leistung:
-23.97%
Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile
Firmenname
Phathom Pharmaceuticals Inc
Sektor
Branche
Telefon
(877) 742-8466
Adresse
100 CAMPUS DRIVE,, FLORHAM PARK, NJ
Vergleichen Sie PHAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PHAT
Phathom Pharmaceuticals Inc
|
13.90 | 963.93M | 114.04M | -330.15M | -274.85M | -4.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.24 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.61 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.66 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
823.27 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
184.17 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-05-03 | Eingeleitet | Stifel | Buy |
| 2024-01-05 | Bestätigt | Needham | Buy |
| 2023-08-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-03-13 | Eingeleitet | Craig Hallum | Buy |
| 2022-10-21 | Eingeleitet | Jefferies | Buy |
| 2022-05-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2021-05-12 | Hochstufung | Goldman | Sell → Neutral |
| 2021-02-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-02-02 | Eingeleitet | Guggenheim | Buy |
| 2020-06-26 | Herabstufung | Goldman | Neutral → Sell |
| 2019-11-20 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Goldman | Neutral |
| 2019-11-19 | Eingeleitet | Jefferies | Buy |
| 2019-11-19 | Eingeleitet | Needham | Buy |
Alle ansehen
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
How strong is Phathom Pharmaceuticals Inc. stock revenue growth2025 Growth vs Value & Reliable Breakout Forecasts - newser.com
Phathom Pharmaceuticals (Nasdaq: PHAT) to join 5 investor conferences; 90‑day webcasts - Stock Titan
Volume spikes in Phathom Pharmaceuticals Inc. stock – what they mean2025 Biggest Moves & Precise Buy Zone Identification - newser.com
What margin trends mean for Phathom Pharmaceuticals Inc. stockPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Volatility clustering patterns for Phathom Pharmaceuticals Inc.Earnings Trend Report & Daily Growth Stock Tips - newser.com
Is Phathom Pharmaceuticals Inc. a candidate for recovery playMarket Performance Report & Daily Stock Momentum Reports - newser.com
Why Phathom Pharmaceuticals Inc. stock remains a top recommendationProduct Launch & Safe Entry Point Alerts - newser.com
Is Phathom Pharmaceuticals Inc. stock a buy on dipsInflation Watch & Long Hold Capital Preservation Plans - newser.com
Can Phathom Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Big Picture & Real-Time Volume Analysis Alerts - newser.com
Will Phathom Pharmaceuticals Inc. stock reach all time highs in 2025CEO Change & Fast Momentum Entry Tips - newser.com
Comparing Phathom Pharmaceuticals Inc. in custom built stock radarsJuly 2025 Weekly Recap & Community Supported Trade Ideas - newser.com
Can Phathom Pharmaceuticals Inc. recover in the next quarterPortfolio Return Report & Long-Term Safe Investment Ideas - newser.com
Is Phathom Pharmaceuticals Inc. stock positioned for digital transformation2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Finance
AlphaQuest LLC Buys 30,760 Shares of Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap UpTime to Buy? - MarketBeat
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q3 2025 Earnings Call Transcript - Insider Monkey
Will Phathom Pharmaceuticals Inc. stock rally after Fed decisions2025 Breakouts & Breakdowns & Growth Oriented Trading Recommendations - newser.com
Price action breakdown for Phathom Pharmaceuticals Inc.Portfolio Update Summary & AI Based Buy and Sell Signals - newser.com
Phathom Pharmaceuticals’ Q3 Earnings: Strong Growth Amid Challenges - TipRanks
Phathom Pharmaceuticals (PHAT): Forecasts Call for 75% Annual Earnings Growth as Losses Deepen - Yahoo Finance
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 8.9% on Strong Earnings - MarketBeat
HC Wainwright & Co. Raises Price Target for PHAT to $26.00 | PHA - GuruFocus
Will Phathom Pharmaceuticals Inc. stock see PE expansionJuly 2025 Summary & Community Verified Swing Trade Signals - newser.com
Phathom Pharmaceuticals stock price target raised to $20 by Guggenheim - Investing.com Australia
How sentiment analysis helps forecast Phathom Pharmaceuticals Inc.Quarterly Portfolio Report & Accurate Buy Signal Alerts - newser.com
Phathom Pharmaceuticals Reports Strong Q3 2025 Growth - TipRanks
Phathom Pharmaceuticals Q3 2025 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
Phathom projects $1B GI market opportunity as sales realignment drives 25% revenue growth - MSN
Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic Shifts - GuruFocus
Phathom Pharmaceuticals Q3 2025 slides: Revenue up 25% as expenses drop 43% - Investing.com
Phathom Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Earnings call transcript: Phathom Pharmaceuticals Q3 2025 earnings beat boosts stock - Investing.com
Phathom Pharmaceuticals, Inc. (PHAT) reports Q3 loss, tops revenue estimates - FXStreet
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q3 Loss, Tops Revenue Estimates - Yahoo! Finance Singapore
Phathom Pharmaceuticals Inc (PHAT) Q3 2025 Earnings: EPS Misses, Revenue Surpasses Estimates with $49.5 Million - GuruFocus
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q3 Adjusted Loss $0.15 per Share, vs. FactSet Est of $-0.46 - MarketScreener
Finanzdaten der Phathom Pharmaceuticals Inc-Aktie (PHAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phathom Pharmaceuticals Inc-Aktie (PHAT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Officer |
Sep 05 '25 |
Sale |
12.09 |
461 |
5,573 |
47,931 |
| Breedlove Robert Charles | Principal Accounting Officer |
Jul 16 '25 |
Sale |
8.36 |
1,692 |
14,152 |
48,392 |
| Topper James N | Director |
May 21 '25 |
Buy |
3.86 |
3,780 |
14,609 |
59,403 |
| Topper James N | Director |
May 14 '25 |
Buy |
3.32 |
6,300 |
20,919 |
55,623 |
| Topper James N | Director |
May 13 '25 |
Buy |
3.16 |
1,120 |
3,543 |
49,323 |
| Topper James N | Director |
May 09 '25 |
Buy |
3.22 |
35,602 |
114,616 |
35,602 |
| Topper James N | Director |
May 12 '25 |
Buy |
3.04 |
12,601 |
38,301 |
48,203 |
| Parikh Asit | Director |
May 06 '25 |
Buy |
2.60 |
5,000 |
13,000 |
90,500 |
| Parikh Asit | Director |
May 07 '25 |
Buy |
2.40 |
5,000 |
11,984 |
95,500 |
| Henderson Molly | CFO and CBO |
Apr 07 '25 |
Sale |
4.55 |
3,678 |
16,740 |
89,868 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):